The role of CXCL12 axis in pancreatic cancer: New biomarkers and potential targets

Frontiers in Oncology

Oncology

Emanuela Pilozzi¹  Silverio Tomao²  Giacomo Barchiesi²  Michela Roberto²  Mattia Alberto Di Civita²  Daniele Santini²  Giulia Arrivi³  Federica Mazzuca³  Paolo Marchetti⁴ 

[1] Department of Clinical and Molecular Medicine, Anatomia Patologica Unit, Sant’ Andrea University Hospital, Sapienza University of Rome, Rome, Italy;Oncology Unit (UOC) Oncologia A, Department of Radiological, Oncological and Anathomo-patological Science, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy;Oncology Unit, Department of Clinical and Molecular Medicine, Sant’ Andrea University Hospital, Sapienza University of Rome, Rome, Italy;Scientific Direction, Istituto Dermopatico dell’Immacolata (IDI-IRCCS), Rome, Italy;

关键词: pancreatic ductal adenocarcinoma (PDAC);    CXCL12;    CXCR4;    CXCR7;    chemokines;    biomarkers;    tumor micreoenvironment (TME);   

DOI  :  10.3389/fonc.2023.1154581

 received in 2023-01-30, accepted in 2023-03-09,  发布年份 2023

来源: Frontiers

【 摘 要 】

IntroductionChemokines are small, secreted peptides involved in the mediation of the immune cell recruitment. Chemokines have been implicated in several diseases including autoimmune diseases, viral infections and also played a critical role in the genesis and development of several malignant tumors. CXCL12 is a homeostatic CXC chemokine involved in the process of proliferation, and tumor spread. Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive tumors, that is still lacking effective therapies and with a dramatically poor prognosis.MethodWe conducted a scientific literature search on Pubmed and Google Scholar including retrospective, prospective studies and reviews focused on the current research elucidating the emerging role of CXCL12 and its receptors CXCR4 – CXCR7 in the pathogenesis of pancreatic cancer.ResultsConsidering the mechanism of immunomodulation of the CXCL12-CXCR4-CXCR7 axis, as well as the potential interaction with the microenvironment in the PDAC, several combined therapeutic approaches have been studied and developed, to overcome the “cold” immunological setting of PDAC, like combining CXCL12 axis inhibitors with anti PD-1/PDL1 drugs.ConclusionUnderstanding the role of this chemokine’s axis in disease initiation and progression may provide the basis for developing new potential biomarkers as well as therapeutic targets for related pancreatic cancers.

【 授权许可】

Unknown   
Copyright © 2023 Roberto, Arrivi, Di Civita, Barchiesi, Pilozzi, Marchetti, Santini, Mazzuca and Tomao